News
An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
20h
GlobalData on MSNModerna’s mRNA flu shot outperforms current standard at Phase IIIThe trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.
Pharmalittle: We’re reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more
Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results